infliximab Archives | Page 8 of 17

Federal Circuit Court affirms judgement of Celltrion v Janssen matter

by Bioblast Editor | Mar 5, 2020 | Other Updates

On 05 March 2020, the Federal Circuit Court affirmed the District Court’s judgement of non-infringement in the Celltrion v Janssen (infliximab) matter.

Celltrion launches Remsima SC in UK

by Bioblast Editor | Mar 2, 2020 | Other Updates

On 02 March 2020, Celltrion launched Remsima SC, its subcutaneous infliximab product, in the UK. To support the launch, Celltrion held a symposium at which it showcased the product and supporting data. Celltrion has signed a framework agreement with the NHS to supply...

Health New England announces savings through utilisation of biosimilar infliximab

by Bioblast Editor | Jan 16, 2020 | Biosimilars updates

Health New England, a nonprofit health plan in Massachusetts, announces savings of $1.7 million in the past year by reaching 93% utilisation of biosimilar infliximab.

Amgen’s Avsola® (infliximab) approved by FDA

by Bioblast Editor | Dec 6, 2019 | Biosimilars updates

Amgen announced that the FDA has approved Avsola® (infliximab) for all Remicade® approved indications.

Biogen and Samsung Bioepis partnership for commercialisation announced

by Bioblast Editor | Nov 6, 2019 | Biosimilars updates

Biogen and Samsung Bioepis announce partnership for the commercialisation of biosimilar ranibizumab and aflibercept for major markets world side including the US, Canada, Europe, Japan and Australia. Biogen has also acquired exclusive commercialisation rights for its...